Also found in: Dictionary.
Related to Aggrenox: dipyridamole


A proprietary combination drug (dipyridamole and aspirin) for preventing new stroke in patients who have suffered a TIA or completed ischaemic stroke.
Indications Pulmonary hypertension, reduces shunt failure in dialysis, increases tPA release from cerebrovascular endothelium, increases perfusion in patients with ischaemic cardiomyopathy.
Adverse effects Dyspepsia, abdominal pain, nausea, diarrhoea, vomiting, headache, haemorrhage, epistaxis, purpura, anaemia.
References in periodicals archive ?
Aggrenox (aspirin/extended-release dipyridamole) had annualized sales of approximately $331 million for the twelve months ended May 2008, based on IMS sales data.
The study results are consistent with the outcome of the earlier European Stroke Prevention Study-2 trial (ESPS-2), which demonstrated that Aggrenox is twice as effective for the prevention of secondary stroke as either ASA or dipyridamole alone.
In further exploratory analysis of the main secondary endpoint of the composite of stroke, myocardial infarction or vascular death, AGGRENOX and clopidogrel showed similar outcomes (13.
Barr filed its ANDA containing a paragraph IV certification for a generic Aggrenox product with the U.
The primary endpoint (base case analysis) of the study was the cost-effectiveness of Aggrenox vs.
Results from ESPS2 indicate that AGGRENOX reduces the risk of recurrent stroke by 37 percent compared to placebo.
Treatment-related adverse events reported by the AGGRENOX group included headache, bleeding, and gastro-intestinal (GI) complaints.
The study consisted of four treatment arms including: AGGRENOX, low-dose aspirin alone, extended-release dipyridamole alone and placebo.
European physicians have found that stopping treatment with Aggrenox for a few days, restarting treatment at one capsule a day and increasing to two a day after a few days has helped people who develop headaches with initial treatment, said Dr.
Promoting the use of Aggrenox as one of the best drugs to reduce the risk of heart attacks and other cardiovascular risks despite the lack of evidence to support those claims.
Our work shows you revenue forecasts for 14 top products, including Plavix, Lovenox, Pradaxa, Pletal and Aggrenox, as well as newer drugs, Effient, Brilinta, Xarelto and Eliquis.